These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33947582)

  • 1. Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020.
    Maltez N; Hughes M; Brown E; Hickey V; Park H; Shea B; Herrick AL; Pauling JD; Proudman S; Merkel PA
    Semin Arthritis Rheum; 2021 Jun; 51(3):640-643. PubMed ID: 33947582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.
    Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
    Clin Rheumatol; 2022 Oct; 41(10):3049-3054. PubMed ID: 35583625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain reporting in systemic sclerosis-related Raynaud's phenomenon: An OMERACT scoping review.
    Maltez N; Hughes M; Brown E; Hickey V; Shea B; Herrick AL; Proudman S; Merkel PA; Pauling JD
    Semin Arthritis Rheum; 2023 Aug; 61():152208. PubMed ID: 37202251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working Group.
    Chapman LS; Alcacer-Pitarch B; Pauling JD; Flurey CA; Redmond AC; Richards P; Herrick AL; Merkel PA; Proudman S; Menz HB; Helliwell PS; Hannan MT; Domsic RT; Saketkoo LA; Shea B; Siddle HJ
    Semin Arthritis Rheum; 2024 Apr; 65():152372. PubMed ID: 38325052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients.
    Castellví I; Eguiluz S; Escudero-Contreras A; Ríos JJ; Calvo-Alén J; Callejas-Rubio JL; De la Puente C; Simeón CP; Narváez FJ; Espinosa G; Carreira PE; Rubio-Rivas M; Alegre JJ; Guillén-Del-Castillo A; Román-Ivorra JA; Fonollosa V;
    Rheumatol Int; 2019 Nov; 39(11):1875-1882. PubMed ID: 31522232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
    J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers.
    Herrick AL
    Curr Opin Rheumatol; 2016 Nov; 28(6):577-85. PubMed ID: 27541182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
    Ennis D; Ahmad Z; Anderson MA; Johnson SR
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portuguese Recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases.
    Santiago T; Duarte AC; Sepriano A; Castro A; Rosa B; Resende C; Oliveira D; Dourado E; Costa E; Cunha-Santos F; Terroso G; Boleto G; Silva I; Barbosa L; Silva J; Sousa Neves J; Salvador MJ; Gonçalves MJ; Gomes Guerra M; Miriam Ferreira R; Duarte-Fernandes R; Barreira S; Silvestre Teixeira V; Tomás AL; Romão V; Cordeiro A
    ARP Rheumatol; 2024; 3(2):84-94. PubMed ID: 38956991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domain reporting in Systemic Sclerosis-Related Digital Ulcers: An OMERACT Scoping Review.
    Hughes M; Maltez N; Brown E; Hickey V; Shea B; Pauling JD; Proudman S; Merkel PA; Herrick AL
    Semin Arthritis Rheum; 2023 Aug; 61():152220. PubMed ID: 37236843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.